Patent approved in the United States for Isofol’s drug candidate arfolitixorin
The patent now approved in the United States expires in 2037 and covers both the Active Pharmaceutical Ingredient (arfolitixorin hemisulfate), […]
MAR
Isofol announces that an abstract with new research resultshas been published for this year’s ASCO congress in Chicago
Isofol Medical AB (publ) announces that a scientific abstract has been published for this year’s annual Congress of the American
Isofol reports FDAs feedback from the ongoing special protocol assessment (SPA) process
In March 2018, Isofol Medical AB (publ) submitted a Special Protocol Assessment (SPA) to the United States Food and Drug
Isofol reports successful outcome from the scientific advice with the EMA
Isofol Medical AB (publ) has received positive feedback in scientific advice from the European Medicines Agency (EMA) regarding its candidate
Successful End-of-Phase 2 meeting with FDA and Phase 3 Program for Modufolin® agreed
Isofol Medical AB (publ), developing Modufolin®(arfolitixorin) as treatment for advanced colorectal cancer, has had a successful regulatory meeting with the
Isofol announces that Modufolin® as a rescue therapy in the treatment of osteosarcoma in children is safe and preventive of HDMTX toxicities
Isofol Medical AB (publ) announces that results from the clinical ISO-MTX-003 study suggest that Modufolin® as a rescue therapy, in
Pareto Securities has notified Isofol Medical AB that stabilisation measures regarding the Company’s shares have been taken
In connection with the offering to acquire newly issued shares in Isofol and the listing on Nasdaq First North Premier
Pareto Securities has notified Isofol Medical AB (publ) that stabilisation measures regarding the Company’s shares have been taken
In connection with the offering to acquire newly issued shares in Isofol and the listing on Nasdaq First North Premier